Coenzyme Q: food sources, adequate and clinically effective doses

Author:

Kodentsova V. M.1ORCID,Risnik D. V.2ORCID,Sarkisyan V. A.1ORCID,Frolova Yu. V.1ORCID

Affiliation:

1. Federal Research Centre of Nutrition, Biotechnology and Food Safety

2. Lomonosov Moscow State University

Abstract

Coenzyme Q (CoQ) plays a key role in cell bioenergetics; it is not only supplied with food, but also synthesized in the body. Endogenous CoQ synthesis decreases with age, with statin use, with cardiovascular, neurodegenerative, and other diseases. In this regard, specialized food products (SFP) enriched with CoQ are being developed. Aim of the review – compare the CoQ doses allowed for use as part of dietary supplements and SFP with doses that provide a clinical effect. Literature review was carried out using the RSCI, Pubmed databases and Google Scholar, ReserchGate systems for the keywords “ubiquinone”, “coenzyme Q10”. The amount of CoQ contained in SFP is set by domestic regulatory documents based on an adequate daily intake for adults (30 mg) and the upper allowable intake level as part of SFP and dietary supplements – 100 mg/day. Actually used doses of CoQ range from 60 to 500 mg/day. Various ways to increase the bioavailability of CoQ have been described. When patients take CoQ, a U-shaped dose-effect relationship is observed, an effective dose that significantly reduces systolic blood pressure, fasting glucose and insulin levels, the degree of hemoglobin glycation, the HOMA-IR glycemic test is in the range of 100–200 mg / day. An improvement in the antioxidant status and a decrease of pro-inflammatory cytokines concentration in the blood plasma of athletes is provided by CoQ doses of 60–300 mg/day, in patients with type 2 diabetes mellitus and coronary heart disease, doses of 100–150 mg/day. Clinically effective doses of CoQ (100–200 mg/day) when used for at least 12 weeks correspond to or are 1.5–2 times higher than the upper allowable consumption level in the composition of SFP and dietary supplements. The inclusion of CoQ in the dietary therapeutic SFP in an amount that does not reach doses that are effective in a certain pathology does not achieve the expected result. A possible way to solve the problem is to increase the acceptable levels of consumption of CoQ in SFP, as well as increasing the bioavailability of CoQ in the composition of emulsions, liposomes, phytosomes and oleogels.

Publisher

Remedium, Ltd.

Subject

General Medicine

Reference52 articles.

1. Dzugkoev S.G., Garmash O.Yu., Dzugkoeva F.S. Pathogenetic rationale for using an inhibitor of 3-hydroxy-3-methylglutarylcoenzyme A reductase and an antioxidant coenzyme Q10 in the treatment and prevention of cardiovascular disease. Cardiovascular Therapy and Prevention (Russian Federation). 2021;20(6):2793. (In Russ.) https://doi.org/10.15829/17288800-2021-2793.

2. Díaz-Casado M.E., Quiles J.L., Barriocanal-Casado E., González-García P., Battino M., López L.C., Varela-López A. The paradox of coenzyme Q10 in aging. Nutrients. 2019;11(9):2221. https://doi.org/10.3390/nu11092221.

3. Pallotti F., Bergamini C., Lamperti C., Fato R. The roles of coenzyme Q in disease: direct and indirect involvement in cellular functions. Int J Mol Sci. 2021;23(1):128. https://doi.org/10.3390/ijms23010128.

4. Goroshko O.A., Krasnykh L.M., Kukes V.G., Zozina V.I. Evaluation of Coenzyme Q10 Redox Status as a Biomarker of Oxidative Stress. The Bulletin of the Scientific Centre for Expert Evaluation of Medicinal Products. Regulatory Research and Medicine Evaluation. 2019;9(3):146–152. (In Russ.) https://doi.org/10.30895/1991-2919-2019-9-3-146-152.

5. Zozina V.I., Melnikov E.S., Krasnykh L.M., Goroshko O.A., Kukes V.G. The impact of cardiovascular and bronchopulmonary diseases on coenzyme Q10 plasma concentration. Sechenov Medical Journal. 2019;10(1):16–21. (In Russ.) Available at: https://www.researchgate.net/publication/332057112_Vlianie_serdecno-sosudistyh_i_bronholegocnyh_zabolevanij_na_koncentraciu_koenzima_Q_10_v_plazme_krovi.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3